EZH2 and differentiated thyroid carcinoma: In the context of EZH2‐mediated dedifferentiation, EZH2 represses PAX8 gene expression by targeting its promoter in ATC [16], and in papillary thyroid carcinoma (PTC) cells, a variant of WDTC, Tazemetostat treatment enhances TDGs expression and iodide uptake [17].